Navigation Links
Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium
Date:9/9/2011

, 71 percent of patients in the study had no tumor progression, defined as complete response (CR), partial response (PR) and stable disease (SD), as measured by RECIST criteria.  NKTR-102 also demonstrated a high clinical benefit (CR+PR+SD greater than six months) rate of 46 percent (30 of 66).  Six patients experienced 100 percent resolution of all target lesions, with two complete RECIST responses and four near-complete responses. Objective tumor responses were maintained in heavily pretreated and poor prognosis subsets, including patients previously treated with anthracycline/taxane/capecitabine, patients with metastatic triple-negative breast cancer and patients with visceral disease.  

NKTR-102 exhibited minimal alopecia, neuropathy and neutropenia, which are significant adverse events associated with existing and recently-approved breast cancer therapies.  Side effects were generally manageable; most common Grade 3 toxicity was diarrhea (17-23%) typically occurring after three months of therapy for both schedules.  

Eighty-nine percent (62/70) of patients in the study received a prior anthracycline/taxane with or without capecitabine.  A total of 66 of the 70 patients treated with single-agent NKTR-102 in the Phase 2 clinical study were assessable for the primary endpoint of objective tumor response rate (ORR).  

The slide presentation from today's oral session at the ASCO 2011 Breast Cancer Symposium is available on Nektar's website at http://www.nektar.com/product_pipeline/oncology_nktr-102.html.BEACON Study DesignThe company also announced today the design of the planned Phase 3 clinical trial of NKTR-102 in metastatic breast cancer patients.  The BEACON study (BrEAst Cancer Outcomes with NKTR-102) plans to enroll approximately 840 metastatic breast cancer patients who have had prior treatment with anthracycline, taxane
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
3. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
4. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
8. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
9. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
10. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
11. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin ... a Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities ... update for shareholders detailing why a "YES" vote to increase ... Shareholders, As we reflect upon the 2014 fiscal ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced ... have been enrolled into the Company,s Phase 2 clinical ... safety of Gem,s lead compound, GPX-150 (an investigational medication), ... or metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... , Jan. 22, 2015  BiOptix is pleased to ... as Vice President of Chemistry and Biochemistry. Scott joins the ... AstraZeneca Pharmaceuticals, and Amgen throughout the course of his ... "Scott is a nationally recognized thought leader ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... January 22, 2015 The Incredible Bulk is ... Pakulski to increase lean muscle by up to 30lbs in ... the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. ... is a step-by-step, scientific diet formula that allows the body ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) ... to “Live Fearless.” , The “Faces of Fearless” ... about how they or someone they know has faced a ... the moment. By telling these types of stories through livefearlessmn.com, ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... differs between the sexes, findings show, , TUESDAY, Feb. 2 ... boys, new research indicates. , ""Our study shows that the ... the same in boys as it is in girls," study ... University of Michigan, said in a university news release. "We ...
... , ... will reveal new statistics gathered by the Dark Report at The Executive War College on ... Miami, ... Adam Slone will present the Dark Report,s 2010 Executive Compensation and Benefits Survey at ...
... This release is available in French ... social difficulties simply because of the way they talk, ... McGill,s School of Communication Sciences and Disorders, has learned ... Parkinson,s disease, based solely on how they communicate. These ...
... , , MOUNT LAUREL, N.J. , Feb. 2 ... pleased to announce the opportunity for individuals interested in voluntary ... case manager certification program in the United States . ... CCM® credential, CCMC is dedicated to upholding rigorous standards for ...
... , LOS ANGELES , Feb. 2 LaVelle LaRue ... food! He did this without the help of Lap Band or any other ... a model/actor/comedian, LaVelle LaRue was fed up with eating the same ... did not have the time to cook himself tastier meal choices that were ...
... high risk of schizophrenia , TUESDAY, Feb. 2 (HealthDay ... schizophrenia and other psychotic disorders, fish oil may help ... study included 81 high-risk patients with either mild psychotic ... disorders, plus a decrease in daily functioning. These criteria ...
Cached Medicine News:Health News:Later Puberty Seen for Obese Boys 2Health News:Adam Slone to Present the 2010 Study on Executive Compensation Benefits for the Diagnostic Laboratory Industry 2Health News:Adam Slone to Present the 2010 Study on Executive Compensation Benefits for the Diagnostic Laboratory Industry 3Health News:Parkinson's disease research uncovers social barrier 2Health News:CCMC Accepting Applications for Voluntary Service on its Board of Commissioners 2Health News:CCMC Accepting Applications for Voluntary Service on its Board of Commissioners 3Health News:From 301 lbs Diabetic to Fast Food Six Pack Abs 2Health News:Fish Oil Helped Stave Off Psychosis in Study Patients 2
Inquire...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... ideal for PCR and other ... work where aerosol contamination might ... pipetting DNA/RNA solutions, infectious materials, ... applications requiring absolute sterility, they ...
... contamination, which causes false ... Hydrophobic, nonwicking and self-sealing ... pass through these aerosol-resistant ... to tips with absorption ...
Medicine Products: